India's Supreme Court has raised the alarm. Malaysia should listen before healthcare becomes unaffordable for ordinary Malaysians.
Consider this: a cancer medicine that a retailer buys for about ₹2,700 carries a maximum retail price of ₹27,000. That's not just a question of commercial margins anymore. It becomes a question of public trust, affordability, and the ethics of healthcare.
https://share.google/AzrfgQyg1lvWzKiTt. BAR & BENCH
That's the concern now before India's Supreme Court in Kishan Chand Jain v Union of India. The court has questioned the huge disparities between what retailers pay and the maximum retail price of medicines. It has also questioned situations where corporate hospitals require patients to buy medicines from their own pharmacies. The case is still ongoing, and the court's observations are not a final determination of the underlying issues. The warning has relevance far beyond India.
Malaysia must ask a similar question of to how much can private healthcare charge before healthcare itself becomes financially out of reach?
https://share.google/7HwsnB9QfoYbJX1IY. The Star
This issue matters especially because Malaysians are increasingly caught between two systems. Public hospitals provide affordable care but face capacity and waiting-time pressures. Private hospitals can provide faster access and sophisticated treatment, but the costs can be substantial.
For many families, medical insurance is therefore not a luxury but a necessity.
Yet insurance does not make healthcare cheaper, it changes who initially pays the bill.
A hospital charges the insurer. The insurer pays the claim. The rising cost is eventually reflected in premiums, deductibles, co-payments and policy restrictions. The patient may therefore be protected from one large bill today while facing increasingly expensive insurance tomorrow.
Where public money is ultimately involved, taxpayers can also become part of the chain.
This is why the Malaysian Government's RESET strategy deserves serious attention. The Ministry of Finance, Ministry of Health and Bank Negara Malaysia established the Joint Ministerial Committee on Private Healthcare Costs to address rising private healthcare costs and medical inflation. Its reforms include price transparency, cost-effective healthcare options and changes to provider-payment mechanisms.
Malaysia has already introduced medicine-price display requirements in private healthcare facilities and pharmacies. That is useful, but displaying a price is only the beginning of transparency.
Patients should be able to understand what they are paying for.
Why does one hospital charge substantially more than another for a comparable procedure?
What is the medicine acquisition cost?
What is the pharmacy or hospital mark-up?
What are the professional fees?
What are the facility charges?
What is covered by insurance?
Most importantly, what will the patient actually have to pay?
A patient entering a hospital should not have to become an accountant, lawyer and medical expert simultaneously.
The Government's proposed reforms point towards a better model. The MediAsas pilot, launched in 2026 ahead of planned nationwide implementation in January 2027, is intended to support more affordable and sustainable medical protection. The Government also says it is working with hospitals, insurers and takaful operators to improve the structure and presentation of private hospital bills.
The proposed transition towards Diagnosis-Related Groups (DRGs) is equally important.
Under a conventional fee-for-service model, healthcare providers may be reimbursed according to individual services, procedures and charges. DRG-based payment is intended to move the system towards more standardised payments for clinically comparable episodes of care and greater emphasis on value.
That could help change the question from:
"How many things can be charged?"
to:
"What does this treatment actually deliver for the patient?"
However, reform should not be based on the assumption that every private hospital charge is excessive. Private hospitals have legitimate costs: specialist salaries, nurses, equipment, buildings, technology, pharmaceuticals, maintenance and 24-hour emergency services.
The objective should therefore not be to eliminate legitimate profit.
It should be to prevent unreasonable, opaque or unjustifiable pricing.
Malaysia should now consider a comprehensive Private Healthcare Price and Value Charter.
It could require standardised hospital bills, meaningful pre-treatment estimates where clinically practicable, transparent medicine and device charges, comparable prices for common procedures, clearer disclosure of hospital mark-ups and an accessible mechanism for patients to dispute questionable charges.
There should also be stronger separation between clinical necessity and commercial incentives.
If a patient can safely obtain a prescribed medicine from a legitimate external pharmacy at a substantially lower price, there should be clear and transparent rules governing when a hospital may insist on an in-house purchase.
The principle is simple:
A sick patient must never become a captive consumer.
The Public Accounts Committee has already examined concerns involving rising insurance premiums and private hospital charges, and the Government says its recommendations are broadly aligned with the RESET reform agenda.
The opportunity now is to turn these reforms into measurable outcomes.
Malaysia should publish whether medical inflation is actually falling. It should monitor whether insurance premiums become more sustainable. It should compare the prices of common procedures across hospitals. It should measure patient out-of-pocket expenditure and it should determine whether DRG and other payment reforms are delivering better value without compromising quality.
Healthcare is not an ordinary consumer product. A person facing cancer, heart disease or an emergency cannot simply walk away from the market and shop around.
That is why the relationship between patient, hospital, insurer and regulator must be based on trust.
India's Supreme Court has provided a powerful international reminder of what can happen when the gap between the cost of a medicine and what a vulnerable patient is asked to pay becomes extreme.
Malaysia has an opportunity to act before such questions become even more difficult.
Private healthcare can be commercially viable without becoming commercially opaque.
Healthcare may be an industry, but illness is not a business opportunity. The ultimate measure of Malaysia's healthcare reforms should be whether an ordinary Malaysian can obtain necessary treatment without fearing financial ruin.
K.T.Maran Social Environmental Animal Activist
K.T. Maran (maran.kt@gmail.com) is a content creator under the Newswav Creator programme, where you get to express yourself, be a citizen journalist, and at the same time monetize your content & reach millions of users on Newswav. Log in to creator.newswav.com and become a Newswav Creator now!
The User Content (as defined on Newswav Terms of Use) above including the views expressed and media (pictures, videos, citations etc) were submitted & posted by the author. Newswav is solely an aggregation platform that hosts the User Content. If you have any questions about the content, copyright or other issues of the work, please contact creator@newswav.com.
